Pascal Biosciences Inc
XTSX:PAS
Pascal Biosciences Inc
Common Stock
Pascal Biosciences Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pascal Biosciences Inc
XTSX:PAS
|
Common Stock
CA$13.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Common Stock
CA$123.2m
|
CAGR 3-Years
66%
|
CAGR 5-Years
163%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Common Stock
$1.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
16%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Common Stock
$1.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
29%
|
CAGR 10-Years
26%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Common Stock
CA$148.1m
|
CAGR 3-Years
22%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Common Stock
$513.3m
|
CAGR 3-Years
95%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pascal Biosciences Inc
Glance View
Pascal Biosciences, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-03-16. The firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The firm operates in the segment of biotechnology research and development. The firm is focused on developing cannabinoid-based and targeted therapeutics to fight cancer. Its cannabinoid portfolio includes PAS-403, PAS-393 and Cannabinoid for corona virus disease-2019 (COVID-19). Its PAS-403 is a small molecule therapeutics for the treatment of glioblastoma. Its PAS-393, is an immune-stimulatory cannabinoid used in combination with checkpoint inhibitor therapy to treat multiple cancers. In addition, it is developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.
See Also
What is Pascal Biosciences Inc's Common Stock?
Common Stock
13.1m
CAD
Based on the financial report for Nov 30, 2022, Pascal Biosciences Inc's Common Stock amounts to 13.1m CAD.
What is Pascal Biosciences Inc's Common Stock growth rate?
Common Stock CAGR 1Y
0%
Over the last year, the Common Stock growth was 0%.
